Presentation style format, and I'll be talking a little bit about the quarterly highlights. We'll be jumping into some of those matters in a little bit more detail. We do have a number of questions. There'll be a Q&A section at the end. However, we have tried, where appropriate, to address some of those questions in the deck and with the commentary. So if those questions are dealt with, we'll not be dealing with them again at the end of the presentation in the Q&A slide. So in terms of activity quarterly summary, obviously continuing to see growth in our OEM Pascal business driven primarily by orders from Lumos for the FebriDx product. We know that Lumos have indicated a CLIA waiver decision from FDA at some point in the coming months, and we have already commenced an operational expansion program.
We'll talk a little bit about what that's involving, but that's really to make sure we have capacity available for existing and new customers over the medium period. Really pleased to see continued demand for our HIV self-test product in Africa. I'm very thankful for the Global Fund for that significant order. Really proud of the work we do there. We think it's a really important part of our business and keen to continue to support that part of the business, as well as obviously putting volume through our factory in South Africa. Really excited about the license that we've signed with Burnet, obviously expanding that really valuable strategic partnership with them. They have proven themselves to be a world leader in the development of really novel rapid test assays, and I think combined with the Atomo platform and our go-to-market expertise, that's a really valuable long-term partnership.
I'll be talking a little bit about the liver test and some of the opportunities that we see for that product. Really pleased to talk to you guys today about some new OEM customers for Pascal. We have been talking for quite some time about a pipeline of interested parties. I think the interested parties have been very pleased to see the performance that Pascal has helped the FebriDx test deliver and CLIA waiver studies, and that's obviously been really helpful for us in getting some of those customers over the line. For the quarter, we've seen our revenue at AUD 1.5 million up, more than double on the last quarter.
We received AUD 1.17 in customer receipts, just over AUD 1 million in grants and R&D rebates, and that's allowed us to close out our 31 December cash on hand balance at just over AUD 3.5 million, which is slightly up on the prior quarter close. That allows us to obviously execute on our near-term business plans as we move forward through FY26 and into FY27. Let's jump into some of these in a little bit more detail. I'd like to just, I suppose, summarize progress that's been made to date this financial year. We have seen some solid appreciation in terms of market momentum. Trading volumes are up. The share price is obviously up.
From the start of this FY, it's up 170%, and we are really pleased to see that momentum and hope to see that continue as we look to bring more positive developments to the story and more growth in the business as we roll forward. But that has been encouraging. In terms of our Appendix 4C, obviously very focused on cash burn over the period, less than AUD 1 million over the first half year to date in terms of net cash from operating activities. This particular quarter was positive, so we are able to conserve some of that cash and apply it to opportunities that grow value. And we're very focused on grant-based opportunities where we can get products to market without having to use our cash balance to fund development. In the case of syphilis, we did that through the grant.
In the case of Burnet, we've done that through an assay that they've spent a lot of time and money to develop and get to this stage. So we'll talk a little bit more about those, but it has allowed us to close out the end of 31 December balance at just over AUD 3.5, which is good to see. In terms of the financials for the quarter, obviously we've been able to bring in cash outflows. That reflects, I think, an ongoing focus on operating expenses in the business, and that's something we continue to stay very focused on. We have delivered revenue of AUD 1.5.
That growth's made up of some growth in HIV, and we have noted some good sales in HIV post the end of that quarter, but most of that has been growth in the OEM business, primarily Pascal, and that's been driven from Lumos through the FebriDx business. We do expect to see continued growth in both of those segments of the business, as well as new products coming to market over the period. That's allowed us to continue to run the business with a tight control on cash, and we note that the CRC-P and R&D rebates subsidize a lot of our activities and allow us to run these programs to market on reasonably lean operating budgets, which is obviously helpful. We'll move now to talk about some of the developments over the period in terms of tests and products.
We'll start with HIV being our core finished product business. We continue to see long-term opportunity in HIV self-testing driven by an adoption of self-testing and pharmacy retail channels. We've previously announced progress in Australian adoption in markets like the U.K. through Boots and Tesco's, and we don't see that transition to consumer health abating anytime soon. We think that is only going to pick up momentum as the range of products available increases and consumer acceptance to testing at home continues to develop. We're also very proud of the efforts that we've made to help bring HIV self-test into the public health sphere of government thinking, and we're pleased to see that the federal government has agreed to and committed to funding those self-test HIV programs over the longer term.
We've been very supportive, instrumental, you could say, in getting some of those pilot programs established and validated, and we work very closely with the partners in those programs to make sure they have product available. We continue to support them and the Australian government in that program. We continue to see growth in the business outside of Australia. We launched last year in New Zealand. We've brought on a very experienced commercial resource just before Christmas, someone with a lot of healthcare experience both in public health and in pharmacy retail, and he will be looking to grow not only our existing HIV business but has a mandate to really launch the product into other markets where we don't currently see revenue.
We're very focused on, in particular, Eastern Europe and Southeast Asia, where we see a lot of opportunity for the product, and not just the self-test HIV product, but other products coming behind that. So we do continue to expect to see good momentum in that HIV business over the medium term. In terms of syphilis, we have made good progress on the program development to market. We continue to see a lot of interest from public health. We note that the Australian government last year designated it a priority disease.
We're continuing to see a large level of key opinion leader and clinical interest, primarily in Australia but also in the U.K. and the U.S., and that really reflects the fact that syphilis is out of control and point-of-care options for screening are really limited by the fact that, one, tests are not that easily deployed, and our Pascal solution really addresses that, and two, that there's no test that can accurately distinguish between antibody-positive results that are because of infection and antibody-positive results that are due to prior treated infection. As that pool of prior treated cohort grows, the efficacy of those tests becomes increasingly compromised. Our test has proven, in preliminary verification and clinical testing in Australia, a best-in-class level of specificity that we think is very appealing to clinicians, and we know that from the feedback that we've had from those clinicians.
So we do see very significant opportunities for this product, not only in the existing pharmacy retail channel that we've opened up with HIV, but also in the public health response to syphilis channel. We have had discussions with both federal and state governments. They're aware of this test coming to market, and we do see an opportunity for dual screening of both HIV and s yphilis at-risk patients. There are two cohorts that aren't identical, but they're certainly significantly overlapping in terms of risk, so we do see a real opportunity there. We'll keep the market informed of progress. We have had positive engagement from regulators, and that's allowed us to now move into a phase where we're finalizing our go-to-market regulatory and clinical planning, and we'll be looking to start trials before the end of this financial year.
We are in the process of doing a tech transfer out of Burnet into an ISO 13485 certified facility that can support validated production for sale, and once that's complete, we'll be looking to do those builds and start those trials. So that remains on track, and I think commercially that opportunity continues to build momentum. We're now going to talk a little bit about the latest product that we're adding to our portfolio, and that is an ALT liver function test. Hugely excited about this test. I think it has enormous commercial and clinical application across a very broad range of common chronic conditions. There are a lot of chronic conditions where the liver is significantly impacted by those diseases or by medications, and ALT is a very common biomarker that really measures liver inflammation, and there's good correlation between it and a range of diseases.
Burnet have, as a result, spent a lot of time and a lot of money developing an assay that has good sensitivity and specificity for measuring ALT as a biomarker. We've worked with them for over a year on the Pascal integration of that test onto the platform, and we've made good progress both in terms of development de-risking as well as verification and clinical validation to show the performance of that test in the field. So we know it works. We're very excited about the performance. We know Pascal works very well from the FebriDx CLIA waiver usability feedback, so we're very excited about taking this product to market. We wanted to clarify from our announcement last week around the license that the worldwide license is for the field of point-of-care testing, so that essentially covers all testing outside of laboratories.
So that is hospital clinic wards, CLIA waiver clinics, doctor's offices, decentralized community screening, nurses, as well as commercial applications in the home through either doctor-prescribed or over-the-counter testing. So we have the exclusive license for all of those markets. That could be a visually read test. It could be a test that is read in an app. It could be a test that clips into your reader. We have exclusive rights to manufacture and supply all of those markets with this biomarker under this agreement with Burnet, and we've got a very good working relationship with them. We're very excited about that. The first application that we're targeting is for monitoring of drug treatments where there's a known risk of liver toxicity, liver injury, and Burnet had previously engaged with a very large multinational pharma company for a clinical trial in the U.S. to assess that.
We had previously announced to market a supply of 20,000 cassettes to Burnet for that purpose. That trial is underway, and obviously once the results of that trial are available, we'll be able to use that to develop a clinical plan for that particular application being monitoring for drug-induced liver injury. And that could be in trials, or that could be for patients going on to treatments in the early phases of treatment to make sure that their livers can essentially tolerate that treatment, and that's a fairly sizable range of drugs that do have liver risk injury attached to them. Outside of that, there's a number of other applications that we'll talk to on the next slide, but I think this slide really tries to, on the development side of things, really just reiterate that the test is developed.
We do have working product, and a lot of that work will obviously reduce the timeline to market for a development. We're not starting from scratch. We have the bulk of that work already available from the program that we've put together with Burnet over the last 18 months. In terms of commercial opportunity, a number of very significant markets we believe this test is uniquely designed to address. There are a lot of drugs coming to market and on the market that have toxicity risk, and this test could be deployed as a companion diagnostic, or it could be deployed as an adjunct test just to manage the entering onto treatment of certain drugs that have a risk injury associated with it, and that could be through doctor monitoring, or it could be in the home in a self-test version.
We're looking at both versions of that, and that's a large addressable market in countries where we have high healthcare costs and good margins. Another big opportunity is to use the test to assess liver impact from viral infections, in particular hepatitis, but not limited to hepatitis. We know that ALT is a biomarker that's expressed with people who are suffering from Hep B and Hep C, as well as other viral infections, and we believe that there is an opportunity to monitor and screen for the decision to go on to treatment in some markets where you only go on treatment if you have the disease at a certain stage, or to ensure that treatments have been successful and ALT readings have returned to normal. There is a trial being planned through a U.K. partner for Africa later this year.
We'll come to market with some information on that. Outside of that, there are big, big opportunities for the test being used to screen and monitor chronic conditions such as fatty liver disease and liver disease from alcohol use, and they're extremely big markets, estimated to be about one-third of people closely associated with bad diets and obesity, so that's a very large market opportunity. We do need to do some more work to really establish the best method of deploying this test into those populations, but we see enormous opportunities longer term for this test in all of those areas, and we're very, very excited about the clinical opportunity that this product brings, both in terms of professional in-clinic applications as well as at-home monitoring for health conditions longer term. Obviously, as our plans develop, we'll certainly keep the market informed, but this is one to watch for sure.
Wanted to talk now about some OEM customer growth outside of Atomo finished products. Obviously, we have been saying for some time that we feel Pascal is by far the best delivery format for rapid blood testing in the market. I think that message is starting to be not only validated by third parties such as Lumos, but also recognized beyond our existing network as the performance really starts to sort of separate itself from the competition in terms of what it can deliver. That, plus the ability to support really good in-field clinical data and reliability, has allowed us to take some pipeline discussions and move them to a point where we're ready to lock in new customers. Due to the nature of the products, and one in particular that's extremely novel and disruptive, we're not going to talk about applications and name partners at this stage.
We have indicated that these are international customers with novel products. They have bought, in the case of one of them, a substantial quantity of Pascal units to validate and use for their clinical go-to-market and regulatory approvals, so that's a very significant commitment from them, and we do expect to turn that into a full long-term supply agreement in the coming months. We also have another customer who has worked with us, and we've charged them development fees to do feasibility work on Pascal and show improved performance, and they're very happy with those results, and we're now expecting an order for a quantity similar to the UK customer for V&V and go-to-market regulatory. They will obviously lead, we believe, to supply agreements that then in turn will lead into long-term supply arrangements such as the ones we have with NG and with Lumos.
I think what we also want to suggest is that these are the first of a number of customers that will find their way onto the platform as the utility and performance and reliability of our device becomes increasingly recognized, and I do still believe that over the next three to five years, this will become the gold standard for at-home testing and CLIA-waived in-clinic testing globally. I'm very excited about that. That brings me on to the last slide, which really talks about how we future-proof that revenue, and that's really through an operational upgrade to our capacity. We have a machine in the U.S., Mk1, that's been running. It's validated. It supports both Lumos and NG Biotech and has been used historically for customer R&D work.
We built some time ago a blister machine 2 in Sydney, and that's been used to do all of the new customer development. We've now taken that out of our partner's facility where it was built and put it into an Atomo facility that we're now going to run directly. That allows us to scale up our blister production, which is the blister that sits under the button in Pascal, as well as in Florey, as well as in Curie, and that gives us total capacity once validated of about 12, potentially up to 15 million per annum, and that future-proofs that supply chain for us. It gives us dual source. It gives us more control, and it gives us greater capacity. Over time, that will also turn into improved cost of goods and reduced lead time. So we're very excited about that.
That'll be ongoing through this year, and we'll look to have these products validated and available through the Sydney facility under Atomo QMS by the end of this calendar year. So that's, I think, a sense of the confidence that we have in the demand for Pascal, the confidence that we have in the test that we're bringing forward on Pascal, and I think as we move forward, there's a lot of upside for the business over the next 3-5 years. I'm very excited about that, and I'd like to thank shareholders for continued patience and belief in the company and the technology. That's the end of the presentation. There is a Q&A section. We did have a question on when we thought we might be starting our clinicals with syphilis. I think we've answered that. We're hoping to do that in the next 3-6 months.
In terms of the question around when we expect to submit regulatory dossiers for liver, we need to obviously review the clinical data for drug-induced liver injury application. That will be the first to market. Once we have that, we'll be able to put some guidance out around when that will happen, and then beyond that, there will be other applications that will probably need their own clinical studies because they have different end users and different end points, but the test and the bulk of the dossier will remain the same because the test is unchanged other than the application use. So I hope that answers those two questions. We do have some other questions. One was in relation to when we can expect waiver. I'm assuming that applies to or relates to the FebriDx CLIA waiver. It's not our product. We're not the listed manufacturer.
We're not the one dealing with the FDA, so I'm not going to provide any comment on when that might be anticipated other than to point shareholders back to public disclosure from Lumos on that particular matter. There was another question that related to our thoughts on continued losses in the business. What I will say is, as we've shown this half year, our losses continue to reduce. We have been able to grow the business revenue over the period, and we expect to continue to see that revenue grow without a corresponding growth in operating costs, and that's, I think, hugely encouraging. We have seen our losses quarter on quarter come down, and that's a trend that continues beyond this quarter into the next FY. We're obviously very mindful of not using cash where we don't have to. That's why the business has been run lean.
That's why we are looking to partner with companies and organizations like Burnet, who've done a lot of the R&D work themselves or get grants from the government to support the go-to-market validation. Those grants allow us to essentially not utilize cash on hand to get products to market, and we're going to continue to focus on that. Excuse me, I'm just getting a little bit dry. I'm just going to go and see if there's any other questions that have come in during the period. Yes, there's been a question on any news on the swab test when you think it'll be developed and ready for supply. I think the answer for the swab test is similar to the answer for Florey, the little clip-in version of Pascal for blood testing, and that is that we have the development done to a point where we've proven the utility.
We've proven the usability, but both of those products need to be optimized for the test that they are used with, the specific cassette, the specific swab in the case of the Curie device. So rather than us preemptively try and second-guess who those partners might be, our plan is to find those partners and then bring the product to market for a specific application. It means that we can finish off the detailed tooling and validation for a specific application and ideally have that partner help fund that. So they are very much in our commercialization plan, but we're going to find some customers that want to pay to get them to market first under an OEM model. I hope that answers that particular question. There don't appear to be any others, so I'm going to thank everyone very much for their time today. I'm excited.
I think we've had a good set of results in terms of the growth in revenue, the opportunities moving forward. We're very mindful that we need to deliver, and we're going to continue to look to do that, and we'd like to thank shareholders for their ongoing support. We'll welcome you back for the half-year report next month, and we'll, in that report, start to look a little bit longer term at what some of our plans are and where we think we might be as a company in three to five years, so I'd encourage you all to put that in your diary. Thank you very much. Have a great day.